Let's keep our eye on the real prize in the arena that RMHB has ventured into with the intent of being the best of show via Branding - on multiple fronts including a strong footprint into CBD products as well as multiple product development.
I strongly believe after all is said and done that by the end of 2022 RMHB might have just 1-2% of CBD sales but by projections that would put RMHB at a pace for 400mm a year in sales..( If I use the 105mm shares OS currently +30mm reg on shelf for future use - so using all then - 135mm shares total - doing around 400mm/yr business - even at a low P/E of 6 - would put us around $20 share valuation )
Now is the timefor cost ave down as each new news piece is announced. I myself want to continue loading low and ave down till the Mx deal is announced as a live ongoing deal with product on the way - before we really spike.
As always wishing all longs the best as we enter into the real wheelhouse and navigate what's ahead of us - with confidence as we have a solid mang. team positioning us for huge runs come 2022
Rock on RMHB
Dadon_111
U.S. CBD sales could hit $22 billion annually within four years
CBD is the nonpsychoactive cannabinoid best known for its perceived medical benefits -- and I say "perceived" because the only recognized benefit of CBD, according to the Food and Drug Administration (FDA), is its treatment of two rare forms of childhood-onset epilepsy via approved drug Epidiolex. It can be extracted from the cannabis plant or hemp plant, the latter of which tends to be the most cost-effective means of obtaining large quantities of CBD, since hemp is much easier to grow than cannabis.
Despite having few official conditions that it can treat, according to the FDA, this hasn't stopped CBD sales projections from going through the roof. The Brightfield Group projects that CBD sales in the U.S. could catapult from $591 million in 2018 to $22 billion by 2022, representing a compound annual growth rate of 147%. With CBD possibly comprising half or more of the total cannabinoid market in the U.S. in the years to come, it's become a hot target for cannabis stocks.
But what you might find interesting to learn is that it's not just U.S. companies engaged in this fast-paced CBD industry. Major Canadian growers (i.e., those with at least 100,000 kilos or more of peak production capacity, either individually or via a partnership or royalty interests) have begun piling into the U.S. hemp market.
Why, you ask? Well, for starters, CBD-rich derivative products, such as oils, edibles, sprays, infused beverages, and topicals, offer considerably higher margins than traditional dried cannabis. These derivative products are also the clear consumption choice of a new generation of cannabis users.
More important, entering the U.S. hemp market allows Canadian producers the opportunity to put processing infrastructure in place that could become critical if and when the U.S. federal government legalizes recreational marijuana. Since a legal U.S. pot market would absolutely dwarf Canada's in sales, the entrance into the U.S. is a means for growers to get a leg up on their competition.
https://www.fool.com/investing/2019/06/23/nea...-have.aspx
I strongly believe after all is said and done that by the end of 2022 RMHB might have just 1-2% of CBD sales but by projections that would put RMHB at a pace for 400mm a year in sales..( If I use the 105mm shares OS currently +30mm reg on shelf for future use - so using all then - 135mm shares total - doing around 400mm/yr business - even at a low P/E of 6 - would put us around $20 share valuation )
Now is the timefor cost ave down as each new news piece is announced. I myself want to continue loading low and ave down till the Mx deal is announced as a live ongoing deal with product on the way - before we really spike.
As always wishing all longs the best as we enter into the real wheelhouse and navigate what's ahead of us - with confidence as we have a solid mang. team positioning us for huge runs come 2022
Rock on RMHB
Dadon_111
U.S. CBD sales could hit $22 billion annually within four years
CBD is the nonpsychoactive cannabinoid best known for its perceived medical benefits -- and I say "perceived" because the only recognized benefit of CBD, according to the Food and Drug Administration (FDA), is its treatment of two rare forms of childhood-onset epilepsy via approved drug Epidiolex. It can be extracted from the cannabis plant or hemp plant, the latter of which tends to be the most cost-effective means of obtaining large quantities of CBD, since hemp is much easier to grow than cannabis.
Despite having few official conditions that it can treat, according to the FDA, this hasn't stopped CBD sales projections from going through the roof. The Brightfield Group projects that CBD sales in the U.S. could catapult from $591 million in 2018 to $22 billion by 2022, representing a compound annual growth rate of 147%. With CBD possibly comprising half or more of the total cannabinoid market in the U.S. in the years to come, it's become a hot target for cannabis stocks.
But what you might find interesting to learn is that it's not just U.S. companies engaged in this fast-paced CBD industry. Major Canadian growers (i.e., those with at least 100,000 kilos or more of peak production capacity, either individually or via a partnership or royalty interests) have begun piling into the U.S. hemp market.
Why, you ask? Well, for starters, CBD-rich derivative products, such as oils, edibles, sprays, infused beverages, and topicals, offer considerably higher margins than traditional dried cannabis. These derivative products are also the clear consumption choice of a new generation of cannabis users.
More important, entering the U.S. hemp market allows Canadian producers the opportunity to put processing infrastructure in place that could become critical if and when the U.S. federal government legalizes recreational marijuana. Since a legal U.S. pot market would absolutely dwarf Canada's in sales, the entrance into the U.S. is a means for growers to get a leg up on their competition.
https://www.fool.com/investing/2019/06/23/nea...-have.aspx
14
1
